On February 7, 2022 Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto, "Kyowa Kirin", TSE: 4151) reported that it will make changes to its organization as of April 1, 2022 (Press release, Kyowa Hakko Kirin, FEB 7, 2022, View Source [SID1234607780]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Outline of the changes:
1) The Strategy Division will be newly established.
2) The Corporate Strategy & Planning Department will be split into the Corporate Strategy Department and the Corporate Planning Department, and both departments will be placed in the Strategy Division.
3) The name of the Overseas Business Planning Department will be changed to the Overseas Business Strategy Department, which will be placed in the Strategy Division.
4) The Established Medicine Strategy Department will be newly established and placed in the Strategy Division.
Purpose of the organization changes:
1) Given the development of the business of Kyowa Kirin including its globalization, in addition to consolidating and coordinating each business and product strategy department, to establish a structure to supervise non-financial topics and established medicines as well.
2) To systematically position the functions of supervising its mid-and long-term corporate strategy and managing its corporate plan.
3) To strengthen overseas business strategies and strategic management of regional headquarters.
4) To develop and execute product strategies closely coordinated with business management.
5) To comprehensively grasp the status of established medicines that Kyowa Kirin owns and to supervise business execution to ensure that it proceeds efficiently.